A phase II trial of imatinib in patients with refractory/relapsed myeloma (Q40345307)

19 September 2017

A phase II trial of imatinib in patients with refractory/relapsed myeloma (English)

1 reference

19 September 2017

phase II clinical trial

0 references

1 reference

1

1 reference

19 September 2017

Rafael Fonseca

9

0 references

Martha Q Lacy

series ordinal

3

object named as

Martha Q Lacy

1 reference

19 September 2017

6

S Vincent Rajkumar

1 reference

19 September 2017

2

Morie A Gertz

1 reference

19 September 2017

8

John A Lust

1 reference

19 September 2017

11

Thomas E Witzig

1 reference

19 September 2017

4

Susan M Geyer

1 reference

19 September 2017

10

Jacob Allred

1 reference

19 September 2017

5

Phillip R Greipp

1 reference

19 September 2017

Teresa Kimlinger

7

1 reference

19 September 2017

1 January 2006

1 reference

19 September 2017

1 reference

19 September 2017

47

1 reference

19 September 2017

1

1 reference

19 September 2017

39-42

1 reference

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

19 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F10428190500271269

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500271269

An overview of translocation-related oncogenesis in the chronic myeloid leukaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500271269

Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500271269

Imatinib for systemic mast-cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500271269

C-kit ligand (SCF) in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500271269

Immunohistochemical identification of HER-2/neu overexpression and CD117 (c-kit) expression in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500271269

Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500271269

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500271269

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500271269

Expression and functional role of c-kit ligand (SCF) in human multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500271269

Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500271269

Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500271269

10.1080/10428190500271269

21 January 2018

Identifiers

DOI

1 reference

19 September 2017

1 reference

PubMed ID

16321825